Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Stellar Issues Year-End Results and Highlights from 2013

Published: Friday, January 03, 2014
Last Updated: Friday, January 03, 2014
Bookmark and Share
Company announces financial results and operational highlights for 2013.

Stellar Biotechnologies, Inc. has announced the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013.

Selected Highlights from 2013
New Corporate Partnership: Stellar executed a collaboration agreement with Amaran Biotechnology, Inc. in December 2013, to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy using Stellar’s GMP grade KLH. OBI-822 is the lead immunotherapy product of OBI Pharma, Inc., manufactured by Amaran and currently in Phase II/III clinical trials in the U.S., Taiwan, South Korea, India and Hong Kong, for the treatment of metastatic breast cancer. The collaboration involves an important, multinational clinical project with long-term product development and commercial potential.

Strengthened Balance Sheet: In September 2013, Stellar raised US $12 Million in gross proceeds in a private financing that included a US $5 Million investment by Amaran Biotechnology, Inc., a privately-held Taiwan biopharmaceuticals manufacturer. Proceeds will be used for product research, aquaculture and KLH production development, capital expenditures and working capital. The financing represented continued support from Stellar’s major shareholders, validation from industry investment, and fiscal strength for the Company to execute on its strategic plans

Strategic Program Expansion; Clostridium difficile Active Immunotherapy Platform: In July 2013, Stellar acquired the exclusive, worldwide license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the University of Guelph in Canada. The license broadens Stellar’s business opportunities by adding a strong platform for the Company’s own proprietary active immunotherapy program. In October 2013, the Company announced presentation of positive results from a preclinical study related to the C. diff development program.

Environmental Achievements & Intellectual Property: In 2013, Stellar has announced several milestones further strengthening the Company’s competitive position and barriers to entry around its KLH business. Among these achievements was the industry-first capability to support the complete life cycle of the Giant Keyhole Limpet (Megathura crenulata), the scarce marine mollusk that is the only source for KLH protein. Stellar also announced new patents issued (in U.S. and China) related to its C. diff immunotherapy technology, as well as two U.S. patent applications for new KLH innovations developed at Stellar.

Stellar’s strategic objectives for 2014 are:
• Expand our Stellar KLH™ technology portfolio through ongoing research and development and selective acquisition, while maintaining a strong balance sheet with careful resource management.
• Seize opportunities for commercial growth that build on our strengths and core competencies in KLH development and immunotherapy.
• Identify strategic pathways that leverage our Stellar KLH™ products and expertise into immunotherapy solutions.
• Prepare for transition to major U.S. stock exchange

Frank Oakes, Stellar’s President and CEO said, “We are entering 2014 with unmatched competency in sustainable KLH manufacturing and focused on leveraging this position into new opportunities with key stakeholders and commercial partners in the biopharma industry. We have built high barriers around Stellar’s technology platform, and we are now aggressively expanding with our own immunotherapy development program, further broadening our business potential. This combination of robust platform together with multiple avenues for strategic growth, positions Stellar to capture significant market interest in the future.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Stellar secures strategic site in Mexico for exclusive sustainable KLH production.
Wednesday, August 12, 2015
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Companies sign KLH supply agreement for Neovacs' Kinoid clinical trials and initial commercialization.
Saturday, April 04, 2015
Stellar and Araclon Biotech Sign Exclusive KLH Supply Agreement
Exclusive supply agreement for clinical trials in Alzheimer's active immunotherapies.
Wednesday, November 12, 2014
Stellar and Biovest Sign KLH Supply Agreement
Agreement for BiovaxID immunotherapy for follicular non-Hodgkin's lymphoma.
Tuesday, November 04, 2014
Stellar Biotechnologies Appoints Two Members to SAB
Appointment of Gregory T. Baxter and Charles V. Olson to the Company's Scientific Advisory Board.
Saturday, June 07, 2014
Stellar Biotechnologies Launches New Corporate Website
The new website showcases Stellar's Core KLH products, breakthroughs in aquaculture science, and strategic expansion of its immunotherapy program in a user-friendly platform.
Thursday, May 08, 2014
Stellar Announces Collaboration with Amaran Biotechnology, Inc.
Collaboration agreement to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy.
Friday, December 13, 2013
Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar Expands Senior Leadership Roles with Two Key Appointments
Appointment of Kathi Niffenegger and Catherine Brisson as CFO and COO respectively.
Wednesday, November 06, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Appoints Tessie Che, Ph.D. to Board of Directors
Dr. Che is currently Chair of the Board of Directors of Amaran Biotechnology.
Thursday, September 26, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Facility expansion and cultivation innovations ensure supply leadership.
Tuesday, July 23, 2013
Stellar Biotechnologies & Life Diagnostics Announce Agreement for Stellar Brand KLH ELISA Test Kits
Company to utilize Stellar’s high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies.
Thursday, October 27, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Contribution Increases by Tenfold The Mouse Mutation Resources of One Type Available
The repository provides academic researchers with unique genetic models that are unavailable commercially.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos